Skip to main content
. 2016 Mar 11;11(3):e0150955. doi: 10.1371/journal.pone.0150955

Fig 6. Influence of CYP2D6 genotype on MDMA metabolite formation.

Fig 6

Correlations between CYP2D6 genotype (extensive metabolizers [EM], intermediate metabolizers [IM], and bupropion-pretreated EMs) and AUC24 ratio of the sum of CYP2D6-dependently formed metabolites (DHMA 3-sulfate, DHMA 4-sulfate, HMMA sulfate, and HMMA glucuronide) to MDMA. The data represent individual participants (EM, n = 13; IM, n = 3; EMs after bupropion pretreatment, n = 13). *p < 0.05, **p <0.01, ***p < 0.001, significant difference between EMs and bupropion-pretreated EMs (Wilcoxon matched-pairs test); +p < 0.05, ++p < 0.01, significant difference between bupropion-pretreated EMs and IMs (Mann-Whitney test).